Though therapeutic administration of IFN-α in patients with HCV infection has been mainly associated with induction of ATD, several reports derived from the multiple sclerosis (MS) literature suggest IFN-β as an inducer of ATD among MS patients possibly through stimulation of CXCL10 secretion by thyrocytes (33, 34). This evidence concerns the gene IFNB1 and myeloid sarcoma.